NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination | Biotech Hunter

Enrollment

1,439

Participants

Timeline

Start Date

November 16, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

July 17, 2010

Conditions

Infections, RotavirusRotavirus Vaccines

Interventions

BIOLOGICAL

Rotarix

Two doses of the oral vaccine

OTHER

Data collection

Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.

Trial Locations (18)

GSK Investigational Site, Manila

GSK Investigational Site, Quezon City

GSK Investigational Site, Quezon City

GSK Investigational Site, Pasig City, Metro Manila

GSK Investigational Site, Alabang, Muntinlupa City

GSK Investigational Site, City of Muntinlupa

GSK Investigational Site, Los Banos, Laguna

GSK Investigational Site, Binangonan, Rizal

GSK Investigational Site, Cainta, Rizal

GSK Investigational Site, Gen. Trias, Cavite

GSK Investigational Site, Imus, Cavite

GSK Investigational Site, Makati City

GSK Investigational Site, Manila

GSK Investigational Site, Maybunga, Pasig City

GSK Investigational Site, Pasay

GSK Investigational Site, Quezon City

GSK Investigational Site, Talaba IV, Bacoor, Cavite

GSK Investigational Site, Taytay, Rizal